Ticker brief
RVPH
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
2
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-23 → 2026-06-26 · now +0.28 (−1 bearish … +1 bullish)
Who spoke2
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @StableBread | A | +1.96 | 7 | +0.42 |
| @Quantumup1 | C | -1.95 | 1 | +0.00 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-26 | @StableBread | +0.00 | Links to full RVPH write-up only. | · | tweet ↗ |
| 2026-06-26 | @StableBread | +0.55 | RVPH high-risk multibagger-or-zero thesis with clinical, funding and catalyst timeline. | · | tweet ↗ |
| 2026-06-25 | @StableBread | +0.00 | Links to RVPH deep dive with no standalone thesis. | · | tweet ↗ |
| 2026-06-25 | @StableBread | +0.65 | Bullish RVPH valuation and clinical data thesis compared with JNJ Caplyta deal. | · | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.00 | Raymond James initiated MPLT at Strong Buy with $46 target. | · | tweet ↗ |
| 2026-06-24 | @StableBread | +0.45 | Detailed RVPH thesis says FDA asked for confirmatory Phase 3, creating timeline risk but potential mispricing. | · | tweet ↗ |
| 2026-06-24 | @StableBread | +0.75 | RVPH thesis argues $10M market cap is asymmetric versus cash, late-stage CNS asset and comparable pharma deals. | · | tweet ↗ |
| 2026-06-23 | @StableBread | +0.55 | Long-form bull/bear framework on RVPH patent runway, FDA switch catalyst, and acquirer optionality. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.